---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-000831"
form_type: "8-K/A"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:52:37.443129+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics merger with Trigr completed; Trigr had $99k cash, $15.8M deficit

## Summary
- Trigr audited 2020: cash $99k, total liabilities $2.57M, net loss $2.11M, accumulated deficit $15.8M; going concern doubt.
- Trigr unaudited Q1 2021: cash $4.3M, net income $5.6M from $7M licensing revenue to Elpiscience.
- Merger consideration: 10.27M Compass shares at $4.90/share (~$50.3M) plus up to $9M earnout.
- Trigr lead asset CTX-009 licensed to Elpiscience for Greater China; $7M upfront, up to $110M milestones.

## SEC filing metadata
- accession: 0000950170-21-000831
- form_type: 8-K/A
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/0000950170-21-000831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/cmpx-20210625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-000831
- JSON: https://secwatch.observer/filing/0000950170-21-000831.json
- Plain text: https://secwatch.observer/filing/0000950170-21-000831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.